Homepage Top Section2

The fusion protein, which is being developed for NASH, utilises the HyFc technology of Genexine. It has been developed in-house by South Korean pharma company. The fusion protein

The agency said that as the benefits of Evenity did not outweigh its risks, it recommended refusal of the drug’s marketing authorisation. The marketing authorisation application (MAA) of

The approval allows the drug firms to use Dupixent with other medicines for the treatment of chronic rhinosinusitis with nasal polyposis (CRSwNP) in adults whose disease is not

As per terms of the deal, Allergan shareholders will secure 0.8660 AbbVie shares and $120.30 (£94.8) in cash for each Allergan share. The total consideration will be $188.24

TILT-123 has been engineered to selectively replicate only in cancer cells that produce the TNFa and IL-2 immunostimulatory cytokines locally at the tumour as shown in various in

The EC has approved Talzenna as monotherapy treatment for adult patients with germline breast cancer susceptibility gene (gBRCA)1/2-mutations, who have human epidermal growth factor receptor 2-negative (HER2-) locally

As part of the multi-year collaboration, both the firms will involve in the discovery, development and commercialisation of a pipeline of novel targeted protein degradation drugs for patients

The late-stage trial met its primary multi-component endpoint and showed that linaclotide, in comparison to placebo, improved the overall abdominal symptoms of bloating, discomfort and pain in adult

With the approval, Lynparza can be used as a maintenance treatment for adult patients with advanced (FIGO stages III and IV) BRCA1/2-mutated (germline and/or somatic) high-grade epithelial ovarian,